Kezar Life Sciences Inc (KZR) is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel small molecule therapeutics to treat autoimmune disorders and cancer. Kezar's lead product candidate, KZR-616, is a selective immunoproteasome inhibitor that is currently being evaluated in several clinical trials for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. The company is also developing KZR-261, a dual inhibitor of the immunoproteasome and the lysosome, for the treatment of cancer.
Kezar Life Sciences was founded in 2015 and is headquartered in South San Francisco, California. The company is led by a team of experienced executives and scientists with a track record of developing successful therapeutics. Kezar is backed by leading healthcare investors, including Cormorant Asset Management, EcoR1 Capital, Morningside Ventures, and Vivo Capital.
Kezar Life Sciences Inc (KZR) is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel small molecule therapeutics to treat autoimmune disorders and cancer. Kezar's lead product candidate, KZR-616, is a selective immunoproteasome inhibitor that is currently being evaluated in several clinical trials for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. The company is also developing KZR-261, a dual inhibitor of the immunoproteasome and the lysosome, for the treatment of cancer.